Work

Abstract 4365543: Acoramidis Reduces the Risk of All-Cause Mortality and Cardiovascular-Related Hospitalization Compared With Placebo in Participants With Transthyretin Amyloid Cardiomyopathy and Early-Stage Heart Failure Regardless of Atrial Fibrillation History: Insights From ATTRibute-CM

Year: 2025

Type: conference-abstract

Source: Circulation

DOI: 10.1161/circ.152.suppl_3.4365543

Authors: Ronald Witteles, John Berk, Joshua Mitchell, Keyur Shah, Masatake Kobayashi, Kuangnan Xiong, Adam Castano, Jean-Francois Tamby, Jonathan Fox, Sumeet Mitter, Julian Gillmore, Mazen Hanna

Institutions: Stanford Medicine, Stanford University, Boston University, Washington University in St. Louis, Virginia Commonwealth University, Tokyo Medical University, BridgeBio (United States), Inova Health System, University College London, Cleveland Clinic

Language: English

Topic: Amyloidosis: Diagnosis, Treatment, Outcomes

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7103752358

Cites:

Cited by: 1

Related to: